IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)
Saint Laurent, Quebec--(Newsfile Corp. - December 2, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that its licensing partner Edgemont Pharmaceuticals, LLC (“Edgemont”) has exercised its right to extend the license for the exclusive marketing of Forfivo XL® 450 mg tablets. Under the terms of the extension, Edgemont will retain certain exclusive rights to market and sell Forfivo XL® in the U.S. In exchange, IntelGenx will receive a seven-figure milestone...
2014-12-02 7:30 AM EST
IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
The German Federal Institute for Drugs and Medical Devices ("BfArM") has validated the European Marketing Authorization Application submitted for RIZAPORT™ and initiated its formal review of the application on November 25, 2014 IntelGenx and RedHill continue to work with the FDA to resolve the remaining Chemistry, Manufacturing and Controls ("CMC") issues and secure a compliant source of the raw material, in order to advance potential FDA approval of the U.S. New Drug Application submitted by...
2014-12-01 8:00 AM EST
IIROC Trade Resumption - IntelGenx Corp.
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2014) - Trading resumes in: Company: IntelGenx Corp.
2014-11-26 8:53 AM EST
IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
Saint Laurent, Quebec--(Newsfile Corp. - November 26, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL® 450 mg tablets. Under the terms of the settlement, Wockhardt has been granted the rights, with effect from January 15, 2018, to be the exclusive marketer and distributor of an authorized generic of Forfivo XL® in the U.S. The Company will hold a call to...
2014-11-26 8:38 AM EST
IIROC Trade Halt - IntelGenx Corp.
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2014) - The following issues have been halted by IIROC: Company:
2014-11-25 9:35 AM EST
IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
Saint Laurent, Quebec--(Newsfile Corp. - November 25, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL® 450 mg tablets. The Company will hold a call to discuss details of the settlement on Wednesday, December 3, 2014 at 10:00 AM ET. A live broadcast of the call will be available through the Company's website at www.intelgenx.com. Following the live call, a...
2014-11-25 8:00 AM EST
IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference
Saint Laurent, Quebec--(Newsfile Corp. - November 18, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time. Institutional investors that wish to...
2014-11-18 8:00 AM EST
IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update
Saint Laurent, Quebec--(Newsfile Corp. - November 12, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced financial results for the three and nine months ended September 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated. Financial Results: Cash on hand at September 30, 2014 decreased to $4.4 million and compares with a cash balance of $5.0 million as at December 31, 2013. The...
2014-11-12 8:00 AM EST
IntelGenx Announces Successful Clinical Study for Schizophrenia
Saint Laurent, Quebec--(Newsfile Corp. - November 3, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx" or the "Company") today announced the successful completion of a pilot clinical study for INT0036 that demonstrated a significantly improved pharmacokinetic profile against the reference product. INT0036 is indicated for the treatment of schizophrenia and utilizes the Company's proprietary VersaFilm™ technology. The study data confirm that buccal absorption of the drug from the...
2014-11-03 8:00 AM EST
IntelGenx Founder Returns as President and CEO
Saint Laurent, Quebec--(Newsfile Corp. - October 2, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that its board of directors unanimously decided to appoint the company's founder, Dr. Horst G. Zerbe, as President and Chief Executive Officer. Dr. Zerbe led the company in the same roles from April 2006 to December 2013 and also has been serving as interim President and CEO since July 2014. "As both a pioneer and expert in drug delivery systems, there is no...
2014-10-02 8:00 AM EDT
IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)
Saint Laurent, Quebec--(Newsfile Corp. - October 1, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focused on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, that they have submitted a Marketing Authorization Application...
2014-10-01 8:00 AM EDT
IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference
Saint Laurent, Quebec--(Newsfile Corp. - September 17, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research 9th Annual Best of the Uncovereds Conference to be held Monday, September 22, 2014 at the Luxe Hotel in Los Angeles, California. IntelGenx' presentation will take place September 22, 2014 at 9:30 AM Pacific Time. Institutional investors that wish to...
2014-09-17 8:09 AM EDT
IntelGenx to Present at the Rodman & Renshaw Global Investment Conference
Saint Laurent, Quebec--(Newsfile Corp. - August 21, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference to be held September 9, 2014 at 9:35 a.m. Eastern Time. The Rodman & Renshaw Conference will take place at The New York Palace hotel on September 8-10, 2014. To learn more about the conference, please visit: http://www.rodm.com...
2014-08-21 2:18 PM EDT
IntelGenx Reports Q2, 2014 Results and Provides Corporate Development Update
Saint Laurent, Quebec--(Newsfile Corp. - August 7, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced financial results for the three and six months ended June 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated. Financial Results: Cash on hand at June 30, 2014 increased to $5.2 million and compares with a cash balance of $5.0 million as at December 31, 2013. The increase in cash on hand at...
2014-08-07 8:00 AM EDT
IntelGenx to Host Management Call
Saint Laurent, Quebec--(Newsfile Corp. - July 18, 2014) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that its interim CEO, Dr. Horst G. Zerbe, will be hosting a conference call on July 23rd, 2014 at 10:00 AM Eastern Time. During the conference call, Dr. Zerbe will provide a business update and discussion regarding the Company's recent management changes. After management's comments, the call will be opened for questions. An accompanying webcast will...
2014-07-18 12:36 PM EDT
IntelGenx Announces Management Changes
Saint Laurent, Quebec--(Newsfile Corp. - July 15, 2014) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") announced today that the board of directors (the "Board") of IntelGenx has accepted, with immediate effect, the resignation of Dr. Rajiv Khosla as President and Chief Executive Officer ("CEO") of IntelGenx and as a member of the Board. Effective immediately, the Board has appointed Dr. Horst G. Zerbe to serve as IntelGenx' interim President and CEO until a successor...
2014-07-15 1:06 PM EDT
IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright
Saint Laurent, Quebec--(Newsfile Corp. - July 1, 2014) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that H.C. Wainwright has initiated equity analyst coverage of IntelGenx. H.C. Wainwright initiated coverage of IntelGenx with a "buy" rating and price target of $2. The stock closed at US$0.70 on the OTCQX and at CAD$0.74 on the TSX-V last Friday. A copy of the initiation report can be accessed by clicking:...
2014-07-01 8:00 AM EDT
IntelGenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014 for Anti-Migraine VersaFilm(TM) Product
Saint Laurent, Quebec--(Newsfile Corp. - May 21, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focused on oral drug delivery, today reported, together with RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, positive results from a comparative bioavailability study with their anti-migraine...
2014-05-21 8:00 AM EDT
IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product
Saint Laurent, Quebec--(Newsfile Corp. - April 24, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, together with RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of their...
2014-04-24 8:05 AM EDT
IntelGenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology
Saint Laurent, Quebec--(Newsfile Corp. - April 16, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA") from the United States Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No. 12/836,810 entitled "Oral mucoadhesive dosage form" which covers IntelGenx' proprietary AdVersa™ mucoadhesive drug delivery technology. This NOA...
2014-04-16 8:00 AM EDT